The purpose of the study is to determine if ianalumab is more effective than a placebo in improving the condition of patients with active Sjögren’s syndrome. Participants in the study will receive the treatment or placebo through an injection under the skin, known as a subcutaneous injection, over a period of 52 weeks. Throughout the study, participants will be monitored to assess changes in their symptoms and overall health.

This trial aims to provide valuable information on the safety and effectiveness of ianalumab for treating Sjögren’s syndrome, potentially offering a new option for managing this condition. Participants will be closely observed by healthcare professionals to ensure their well-being and to gather data on how the treatment affects their symptoms over time.

The purpose of this study is to assess the safety of cizutamig in patients with these severe inflammatory conditions and to examine how well the treatment works in controlling disease activity. During the study, patients will receive the medication and will be closely monitored for any side effects, particularly Cytokine Release Syndrome and other treatment-related reactions. The study will track various measures of disease activity specific to each condition, such as skin thickness scores for systemic sclerosis, muscle strength measurements for inflammatory myopathy, disease activity scores for rheumatoid arthritis, and symptom scores for Sjögren’s disease. For patients who have lung involvement, lung function tests will also be performed.

The study will last approximately 52 weeks, with regular assessments at different time points to evaluate both the safety and effectiveness of the treatment. Patients will have measurements taken at weeks 16, 24, and 52 to see how their disease responds to cizutamig. The study will also look at whether patients can reduce or stop other medications they may be taking, how often their disease flares up, and how their overall quality of life and daily functioning change during the treatment period.

The purpose of this study is to evaluate the safety of this cell therapy in patients whose autoimmune disease has continued to progress despite receiving treatments that remove B cells from the body. B cells are a type of immune cell that produces antibodies, and in autoimmune diseases, these cells can contribute to the harmful immune response. The study will specifically look at serious side effects including problems with the immune system’s response to the treatment, such as cytokine release syndrome and nervous system complications, as well as damage to organs that does not improve quickly.

During the study, patients will receive the modified T cell treatment and will be closely monitored for any side effects and how their body responds to the therapy. The study will track whether patients experience any severe reactions and how long it takes for these reactions to resolve with appropriate medical care. Patients participating in this study will have already tried multiple standard treatments for their autoimmune disease without success, including at least one treatment specifically designed to eliminate B cells from the body.

Participants in the study will receive the medication through an intravenous infusion, which means the medicine is delivered directly into the bloodstream through a needle in a vein. During the course of the study, medical professionals will monitor the effects of the treatment on the body over several months. This process includes observing changes in the salivary glands, which are the organs that produce saliva, and the lymph nodes, which are small structures that part of the immune system.

The purpose of the study is to assess how Dazodalibep affects the systemic manifestations, or widespread symptoms, of Sjögren’s Syndrome in participants who have moderate-to-severe disease activity. Participants in the study will receive either Dazodalibep or a placebo over a period of time, and their health will be monitored to observe any changes in their condition. The study will last for several weeks, and participants will undergo regular assessments to track their progress and any side effects they may experience.

Throughout the study, researchers will collect data on various health indicators, such as changes in disease activity scores and other symptoms related to Sjögren’s Syndrome. This information will help determine the potential benefits and risks of using Dazodalibep as a treatment option for this condition. The study is designed to provide valuable insights into the management of Sjögren’s Syndrome and to explore new possibilities for improving the quality of life for those affected by this disease.

The purpose of the study is to assess how well Dazodalibep works in reducing the symptoms of Sjögren’s Syndrome in people who experience moderate to severe symptoms. Participants in the study will receive either the treatment or a placebo, which is a substance with no active medication. The study will last for several weeks, during which participants will have regular check-ups to monitor their symptoms and overall health.

Throughout the study, participants will be asked to report on their symptoms and any changes they experience. The goal is to determine if Dazodalibep can provide relief from the symptoms of Sjögren’s Syndrome and to ensure that it is safe for use. The study will help researchers understand the potential benefits and any side effects of the treatment.

This is an extension study, which means it is designed for people who have already participated in and completed earlier studies of dazodalibep for Sjögren’s Syndrome. Those who join this study will continue to receive dazodalibep treatment for a longer time so that researchers can observe how safe the medication is when used over many months or years. The study will track any unwanted effects that occur during treatment, including any serious health problems that might develop. Researchers will also check if the body develops any immune responses against the medication by looking for anti-drug antibodies, which are proteins the body might make in reaction to the treatment.

Throughout the study, blood samples will be collected to measure the amount of dazodalibep in the bloodstream, which helps researchers understand how the medication moves through and stays in the body. The study is open-label, meaning both the participants and doctors will know that everyone is receiving the active medication rather than placebo. This long-term study allows researchers to gather important information about the ongoing safety of dazodalibep in people with Sjögren’s Syndrome over an extended treatment period.

The study will look at whether IMVT-1402 can help improve the overall disease activity by measuring changes in a scoring system that tracks how different body systems are affected by the disease. Participants will receive either IMVT-1402 or placebo through injections under the skin once a week. The main part of the study will last for 24 weeks, during which doctors will monitor how the disease activity changes from the beginning of the study. The total treatment period can last up to 48 weeks.

People taking part in this study will need to have been diagnosed with Primary Sjogren’s Disease for at least 12 months and have a certain level of disease activity affecting their body systems. They will also need to have specific antibodies in their blood that are commonly found in people with this condition, and they must still have some ability to produce saliva. Throughout the study, participants will have regular visits to check their symptoms and how well the treatment is working.

Before receiving the main treatment, patients will undergo preparation with two medications: cyclophosphamide and fludarabine, which help reduce certain immune cells in the body. The purpose of this study is to determine if this combination treatment is safe and if it can help improve symptoms in patients with these hard-to-treat rheumatic conditions.

The treatment involves receiving the medications through intravenous infusion (delivery directly into a vein). Patients will receive multiple doses of the study medications over several weeks and will be monitored regularly to check how well the treatment works and to watch for any side effects. The study will track various measurements of disease activity and symptoms specific to each condition to determine if the treatment is effective.

The purpose of the study is to evaluate the effectiveness of Nipocalimab in improving the symptoms of Sjögren’s Disease. Participants in the study will receive either Nipocalimab or a placebo over a period of time. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results. The main goal is to observe any changes in the disease activity from the start of the study to the end, which is planned to last for several months.

Throughout the study, participants will be monitored regularly to assess their health and any changes in their condition. This will involve routine check-ups and tests to track the progress of the disease and the effects of the treatment. The study aims to provide valuable information on whether Nipocalimab can be an effective treatment option for those suffering from moderate to severe Sjögren’s Disease.

Participants in the study will receive *ianalumab* over a period of time, and researchers will observe changes in the salivary glands. The study will also monitor the safety and tolerability of the treatment, which means checking for any side effects or reactions. Throughout the study, participants will have regular check-ups to assess their health and the effects of the treatment.

The study aims to provide insights into how *ianalumab* works in the body and its potential benefits for people with *Sjögren’s syndrome*. By examining the changes in the salivary glands, researchers hope to better understand the relationship between the treatment and clinical outcomes. This information could help improve future treatments for *Sjögren’s syndrome* and enhance the quality of life for those affected by this condition.

The purpose of the study is to assess the safety of rapcabtagene autoleucel in participants with difficult-to-treat rheumatoid arthritis and severe, refractory Sjögren’s disease with organ involvement. Participants will receive the treatment through an intravenous infusion, which means it will be administered directly into the bloodstream. The study will also involve monitoring the behavior of the treatment in the body, known as cellular kinetics, to understand how it moves and changes over time.

In addition to rapcabtagene autoleucel, the study will also involve the use of other medications, including tocilizumab, fludarabine phosphate, and cyclophosphamide. These medications are commonly used in treating autoimmune diseases and will be administered as part of the study protocol. Some participants may receive a placebo instead of the active treatment. The study aims to gather information over a period of time to evaluate the treatment’s safety and its potential effectiveness in managing these complex diseases.

The purpose of this research is to determine how well sibeprenlimab works in treating Sjögren’s Disease symptoms compared to placebo after 28 weeks of treatment. During the study, participants will receive either sibeprenlimab or placebo through subcutaneous injections. The maximum single dose will be 400 mg, with treatment continuing for up to 52 weeks.

Throughout the study, researchers will monitor various aspects of the disease, including changes in tear and saliva production, fatigue levels, and overall disease activity. The study will also track how well participants tolerate the medication by monitoring their health and any side effects that may occur. Participants may continue taking certain background medications they were already using, such as hydroxychloroquine, methotrexate, leflunomide, or azathioprine, as long as their doses have been stable.

The purpose of the study is to evaluate how effective and safe Efgartigimod is for patients with Primary Sjögren’s Syndrome. Participants in the study will receive either Efgartigimod or a placebo through subcutaneous injections, which means the injection is given under the skin. The study will follow participants over a period to observe changes in their condition, particularly looking at the activity of the disease and any improvements in symptoms.

Throughout the study, researchers will monitor participants to assess the treatment’s impact on disease activity and overall safety. The study aims to provide valuable information on whether Efgartigimod can help manage symptoms and improve the quality of life for those living with Primary Sjögren’s Syndrome. The trial includes an open-label extension, meaning that after the initial phase, all participants may have the opportunity to receive Efgartigimod, allowing further observation of its long-term effects.

The purpose of the study is to assess the effect of Abiprubart on the activity of Sjögren’s Disease. The study will take place over several weeks, during which participants will receive doses of the treatment through injections. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, to ensure unbiased results.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their symptoms. The study aims to gather information on how Abiprubart affects the disease and to identify any potential side effects. This information will help determine if Abiprubart could be a beneficial treatment option for people with Sjögren’s Disease in the future.

Participants in the study will receive ianalumab through subcutaneous injections, which means the medication is administered under the skin. The study will take place over a period of time, allowing researchers to observe how the medication is absorbed and processed by the body. The goal is to ensure that the different forms of administering ianalumab are equally effective and safe for patients. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of ianalumab.

In addition to ianalumab, the study will also involve other medications such as emtricitabine, tenofovir disoproxil, tenofovir alafenamide, and entecavir, which are typically used to manage viral infections. These medications will be administered orally, meaning they are taken by mouth. The study will monitor various health indicators, including any side effects, to ensure the safety and effectiveness of the treatments. The overall purpose is to gather information that could lead to better treatment options for people with these autoimmune diseases.

Participants in the study will receive either the Privigen treatment or a placebo over a period of time. The study aims to see if there is an improvement in symptoms such as pain and overall nerve function. The treatment is given as an infusion, which means it is administered directly into the bloodstream through a vein. The study will also monitor any side effects that participants might experience during the treatment period.

The purpose of this study is to determine if Privigen can effectively treat the nerve-related symptoms associated with Primary Sjögren’s Syndrome. By participating in this study, researchers hope to gather valuable information that could lead to better treatment options for individuals suffering from this condition. The study will last for several weeks, and participants will be closely monitored to assess the treatment’s impact on their symptoms and overall health.

The purpose of the study is to explore how well anifrolumab works in treating primary Sjögren’s syndrome. Participants in the study will receive either the anifrolumab treatment or a placebo, which is a substance with no active medication. The study will last for 24 weeks, during which participants will have regular check-ups to monitor their health and any changes in their symptoms. These check-ups will help researchers understand the treatment’s impact on the disease.

Throughout the study, researchers will assess various aspects of the disease, such as systemic disease activity, patient-reported symptoms, and the function of tear and salivary glands. The study aims to determine if anifrolumab can improve these areas and provide relief to those with primary Sjögren’s syndrome. Safety will also be closely monitored to ensure the treatment is well-tolerated by participants.

The purpose of the study is to evaluate how well these treatment combinations work in improving the symptoms of Primary Sjögren’s Syndrome. Participants in the study will receive one of the treatment combinations or a placebo. The study will last for a period of 24 weeks, during which the participants’ responses to the treatments will be monitored and assessed. The goal is to determine the proportion of patients who show improvement in their symptoms by the end of the study period.

Throughout the study, participants will be closely monitored to ensure their safety and to gather data on the effectiveness of the treatments. This research aims to provide valuable insights into better managing Primary Sjögren’s Syndrome and improving the quality of life for those affected by this condition.

During the study, participants will take the medications orally in the form of film-coated tablets. The trial will assess changes in disease activity and symptoms, such as dryness and joint pain, using various tests and patient-reported outcomes. The goal is to determine if the combination of leflunomide and hydroxychloroquine can improve the symptoms of primary Sjögren’s Syndrome compared to a placebo.

The study will also explore whether certain molecular markers can predict how well a patient might respond to the therapy. This research is part of a larger effort to find more effective treatments for primary Sjögren’s Syndrome and to understand the disease better. Participants will be monitored closely throughout the study to ensure their safety and to gather comprehensive data on the treatment’s impact.

The purpose of the study is to assess how well ianalumab works and how safe it is for patients with active Sjögren’s syndrome. Participants in the study will be randomly assigned to one of three groups: one receiving ianalumab, one receiving a placebo, and another group receiving a standard treatment known as glucocorticoids, which are a type of steroid medication taken orally. The study will last for a total of 52 weeks, during which participants will receive regular injections and have their health monitored closely by the research team.

Throughout the study, the main focus will be on changes in the participants’ health, particularly looking at the ESSDAI score, which is a measure used to assess disease activity in Sjögren’s syndrome. The study aims to demonstrate whether ianalumab is more effective than the placebo in improving this score over the course of the study. Participants will also be monitored for any side effects or changes in their condition to ensure the treatment’s safety and tolerability.

The purpose of this study is to evaluate the long-term safety of efgartigimod alfa in patients who have completed previous studies involving this treatment. Participants will receive the treatment over a period of 48 weeks. During this time, researchers will monitor the participants’ health closely to identify any side effects or changes in their condition. The study will also track various health indicators, such as laboratory test results and vital signs, to ensure the treatment is safe for long-term use.

Throughout the study, participants will have regular check-ups to assess their response to the treatment. The researchers will look for improvements in disease activity and symptoms, as well as any changes in specific markers in the blood. This information will help determine if efgartigimod alfa is a safe and effective option for managing Primary Sjögren’s Syndrome over an extended period.

The purpose of the study is to assess how well ianalumab works over a long period and to monitor any side effects that may occur. Participants will be randomly assigned to receive either ianalumab or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not biased. The study will continue for several years, allowing researchers to gather comprehensive data on the treatment’s safety and effectiveness.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their condition. Blood samples will be taken to measure the levels of ianalumab in the body and to check the number of B-cells, which are a type of immune cell. The study aims to provide valuable information on the potential benefits of ianalumab for people living with Sjögren’s syndrome, contributing to better treatment options in the future.

The purpose of the study is to evaluate how effective and safe deucravacitinib is for treating active Sjögren’s syndrome. Participants will be randomly assigned to receive either the medication or a placebo. The study will last for about a year, during which participants will have regular check-ups to monitor their health and any changes in their symptoms. The main goal is to see if there is an improvement in the disease activity after 52 weeks of treatment.

Throughout the study, participants will be closely monitored for any side effects or changes in their condition. The study aims to provide valuable information on whether deucravacitinib can be a beneficial treatment option for people with Sjögren’s syndrome. This research could potentially lead to new ways to manage the symptoms and improve the quality of life for those affected by this condition.

Participants in the study will receive either the HZN-1116 treatment or a placebo, which is a substance with no active medication. The study will be conducted over a period of time, during which participants will receive regular injections and attend follow-up visits to monitor their health and any changes in their symptoms. The study aims to understand how HZN-1116 affects the overall symptoms and quality of life for those with moderate to severe Sjögren’s Syndrome.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to gather information on how the treatment impacts their condition. The study will help determine if HZN-1116 can be a beneficial treatment option for people living with Sjögren’s Syndrome.

The purpose of the study is to compare the effects of the stem cell treatment with a placebo, which in this case is a simple sterile saline solution. Participants will receive either the stem cell treatment or the placebo through an injection directly into their salivary glands. The study will monitor changes in saliva production over a period of four months to determine the effectiveness of the treatment.

Participants in the study will undergo a series of injections and follow-up visits to assess their salivary gland function. The main goal is to see if the stem cell treatment can increase the flow of saliva in patients with Sjögren’s Syndrome and reduce the discomfort of dry mouth. This research aims to provide new insights into potential treatments for this condition.